Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Operator: Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2025 Earnings and Corporate Update Call. All ...

HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...

How does Mary view her own clinical progress? Assess the problem ... As you and Mary carry out this plan, you note that it seems to be helping her to stay organized. By the end of the week ...

The field of chronic disease management is witnessing a significant transformation due to recent advancements in big data analytics and artificial ...

Two experts have been hand-picked by the federal government to travel the country for six months to gather harrowing stories of bullying as the government forges ahead with its plan to create a ...

today announced financial results for its fiscal 2025 first quarter and provided an update on progress of its clinical development programs. Enobosarm is a next generation drug that makes weight ...

As for secondary clinical endpoints, enobosarm + semaglutide treatment ... whether and when patients will progress into the extension study; the planned design, number of sites, timing, endpoints, ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

The clinical practice update offers 12 “best practice advice” statements on POEM to treat achalasia and other esophageal ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

today provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the Company’s ongoing Phase 2 ...